kunmei Ji

Dr. kunmei Ji

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2021 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
HWHui-Na Wang
Hui-Na Wang
KJkunmei Ji
kunmei Ji
LZLi-Na Zhang
Li-Na Zhang
CXChuchu Xie
Chuchu Xie
WLWei-Yong Li
Wei-Yong Li
JCJiajie Chen
Jiajie Chen
Background: Activator protein-1 (AP1), a c-Fos–JUN transcription factor complex, mediates many cytobiological processes. c-Fos has been implicated in immunoglobulin (Ig)E activation of mast cells (MCs) via high-affinity IgE Fc receptor (FcεRI) binding. This study examined c-Fos involvement in MC activation and tested the effects of the c-Fos/AP1 inhibitor T-5224 on MCs activation and allergic responses. Methods: In vitro studies were conducted with two MC model systems: rat basophilic leukemia cells (RBLs) and mouse bone marrow derived mast cells (BMMCs). MC degranulation and effector functions were examined with β-hexosaminidase release and cytokine secretion assays. c-Fos/AP1 was inhibited with T-5224. c-Fos activity was suppressed with short hairpin RNA targeting c-Fos (shFos). In vivo immune responses were evaluated in passive cutaneous anaphylaxis (PCA) and ovalbumin-induced active systemic anaphylaxis (ASA) models, as well as in an oxazolone (OXA)-induced model of atopic dermatitis, a common allergic disease. Results: c-Fos expression was elevated transcriptionally and translationally in IgE-stimulated MCs. c-Fos binding of the Egr1 (early growth response 1) promoter upregulated Egr1 transcription, leading to production of interleukin (IL)4. T-5224 reduced FcεRI-mediated MC degranulation (evidenced by β-hexosaminidase activity and histamine levels) and diminished EGR1 and IL4 expression. T-5224 attenuated IgE-mediated allergic responses in PCA and ASA models, and it suppressed MC-mediated atopic dermatitis in mice. Conclusion: IgE binding can activate MCs via a c-Fos/Egr1/IL-4 axis. T-5224 suppresses MC activation in vitro and in vivo and thus represents a promising potential strategy for targeting MC activation to treat allergic diseases.

18 July 2018 in Clinical and Translational Allergy
Verified
Journal Article
Open access
PDF file
JHJiayun Hu
Jiayun Hu
JCJiajie Chen
Jiajie Chen
LYLanlan Ye
Lanlan Ye
ZCZelang Cai
Zelang Cai
JSJinlu Sun
Jinlu Sun
KJkunmei Ji
kunmei Ji
Allergic diseases are inflammatory disorders that involve many types of cells and factors, including allergens, immunoglobulin (Ig)E, mast cells, basophils, cytokines and soluble mediators. Among them, IgE plays a vital role in the development of acute allergic reactions and chronic inflammatory allergic diseases, making its control particularly important in the treatment of IgE-mediated allergic diseases. This review provides an overview of the current state of IgE targeted therapy development, focusing on three areas of translational research: IgE neutralization in blood; IgE-effector cell elimination; and IgE+ B cell reduction. IgE-targeted medicines such as FDA approved drug Xolair (Omalizumab) represent a promising avenue for treating IgE-mediated allergic diseases given the pernicious role of IgE in disease progression. Additionally, targeted therapy for IgE-mediated allergic diseases may be advanced through cellular treatments, including the modification of effector cells.

9 November 2020 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
JCJia-Jie Chen
Jia-Jie Chen
LZLi-Na Zhang
Li-Na Zhang
HHHu Hou
Hu Hou
LXLingqing Xu
Lingqing Xu
KJkunmei Ji
kunmei Ji
A severe immune response in patients with coronavirus disease 2019 (COVID‑19) can cause a potentially lethal unconstrained inflammatory cytokine storm, known as cytokine release syndrome (CRS). The present study provides an overview of the biology underlying CRS and how targeted inhibition of interleukin (IL)‑6 signaling may improve outcomes and the survival of patients suffering from COVID‑19. Preliminary clinical results have indicated that antagonism of the IL‑6 receptor (IL‑6R), including with the FDA‑approved humanized monoclonal antibody tocilizumab, can improve the outcomes of patients with severe or critical COVID‑19 while maintaining a good safety profile. The available clinical data support the expansion of clinical trials using IL‑6R targeting inhibitors for severe and critical COVID‑19 treatment.

20 July 2016 in BioMed Research International
Verified
Journal Article
Open access
PDF file
PWPengfei Wei
Pengfei Wei
ZCZelang Cai
Zelang Cai
JHJinwen Hua
Jinwen Hua
WYWeijia Yu
Weijia Yu
JCJiajie Chen
Jiajie Chen
KJkunmei Ji
kunmei Ji
Over the recent decades, China experienced several emerging virus outbreaks including those caused by the severe acute respiratory syndrome- (SARS-) coronavirus (Cov), H5N1 virus, and H7N9 virus. The SARS tragedy revealed faults in China’s infectious disease prevention system, propelling the Chinese government to enact reforms that enabled better combating of the subsequent H1N1 and H7N9 avian flu epidemics. The system is buttressed by three fundamental, mutually reinforcing components: (1) enduring government administration reforms, including legislation establishing a unified public health emergency management system; (2) prioritized funding for biotechnology and biomedicine industrialization, especially in the areas of pathogen identification, drug production, and the development of vaccines and diagnostics; and (3) increasing investment for public health and establishment of a rapid-response infectious diseases prevention and control system. China is now using its hard-gained experience to support the fight against Ebola in Africa and the Middle East Respiratory Syndrome in its own country.

4 February 2020 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
LZLi‐Na Zhang
Li‐Na Zhang
KJkunmei Ji
kunmei Ji
YSYue‐Tong Sun
Yue‐Tong Sun
YHYi‐Bo Hou
Yi‐Bo Hou
JCJiajie Chen
Jiajie Chen

1 October 2021 in Biochemical Pharmacology
Verified
Journal Article
Closed access
JCJiajie Chen
Jiajie Chen
LZLi-Na Zhang
Li-Na Zhang
HWHui-Na Wang
Hui-Na Wang
CXChu-Chu Xie
Chu-Chu Xie
WLWei-Yong Li
Wei-Yong Li
KJkunmei Ji
kunmei Ji